Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Richert

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
HIV Medicine|November 28, 2015
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapyA Winston, W Stöhr, A Antinori, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 21, 2015
Kinetics and dynamics of cyclosporine A in three hepatic cell culture systemsP Bellwon, G L Truisi, F Y Bois, et al.
Journal of Virology|February 11, 2021
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II TrialY Lévy, C Lacabaratz, E Lhomme, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
HIV Medicine|November 28, 2015
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapyA Winston, W Stöhr, A Antinori, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|July 21, 2015
Kinetics and dynamics of cyclosporine A in three hepatic cell culture systemsP Bellwon, G L Truisi, F Y Bois, et al.
Journal of Virology|February 11, 2021
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II TrialY Lévy, C Lacabaratz, E Lhomme, et al.
Pageof 6